Research programme: antisense glucocorticoid receptor antagonists - Ionis Pharmaceuticals

Drug Profile

Research programme: antisense glucocorticoid receptor antagonists - Ionis Pharmaceuticals

Alternative Names: ISIS-377131

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 02 Oct 2007 The agreement between Isis and Ortho-McNeil receives clearance under the Hart-Scott-Rodino Antitrust Improvements Act
  • 17 Sep 2007 Isis and Ortho-McNeil enter into a worldwide collaboration agreement for the discovery, development and commercialisation of antisense drugs for the treatment of metabolic diseases, including ISIS 377131 programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top